| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3075863 | Neurología | 2014 | 12 Pages |
Abstract
New non-ergotine DAs are a valuable option for the treatment of both early and late PD. Despite their good safety profile, serious adverse effects may appear; these effects may have a pathoplastic effect on the course of PD and need to be monitored.
Keywords
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
A. Alonso Cánovas, R. Luquin Piudo, P. GarcÃa Ruiz-Espiga, J.A. Burguera, V. Campos Arillo, A. Castro, G. Linazasoro, J. López del Val, L. Vela, J.C. MartÃnez Castrillo,